X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ABBOTT INDIA NATCO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 13.4 36.7 36.6% View Chart
P/BV x 3.8 9.4 40.7% View Chart
Dividend Yield % 1.2 0.7 158.5%  

Financials

 NATCO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
ABBOTT INDIA
Mar-18
NATCO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,0806,110 17.7%   
Low Rs6713,996 16.8%   
Sales per share (Unadj.) Rs592.11,552.2 38.1%  
Earnings per share (Unadj.) Rs188.4188.8 99.8%  
Cash flow per share (Unadj.) Rs206.3196.4 105.0%  
Dividends per share (Unadj.) Rs8.2555.00 15.0%  
Dividend yield (eoy) %0.91.1 86.6%  
Book value per share (Unadj.) Rs833.6796.6 104.6%  
Shares outstanding (eoy) m36.9021.25 173.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.53.3 45.4%   
Avg P/E ratio x4.626.8 17.4%  
P/CF ratio (eoy) x4.225.7 16.5%  
Price / Book Value ratio x1.16.3 16.6%  
Dividend payout %4.429.1 15.0%   
Avg Mkt Cap Rs m32,311107,376 30.1%   
No. of employees `0004.83.3 145.4%   
Total wages/salary Rs m3,2563,937 82.7%   
Avg. sales/employee Rs Th4,522.59,929.3 45.5%   
Avg. wages/employee Rs Th674.01,185.1 56.9%   
Avg. net profit/employee Rs Th1,439.01,207.7 119.2%   
INCOME DATA
Net Sales Rs m21,84832,985 66.2%  
Other income Rs m4041,170 34.5%   
Total revenues Rs m22,25234,155 65.2%   
Gross profit Rs m9,2845,245 177.0%  
Depreciation Rs m662162 408.9%   
Interest Rs m15438 403.1%   
Profit before tax Rs m8,8726,215 142.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9202,203 87.2%   
Profit after tax Rs m6,9524,012 173.3%  
Gross profit margin %42.515.9 267.2%  
Effective tax rate %21.635.4 61.1%   
Net profit margin %31.812.2 261.6%  
BALANCE SHEET DATA
Current assets Rs m21,30722,655 94.1%   
Current liabilities Rs m5,9206,681 88.6%   
Net working cap to sales %70.448.4 145.4%  
Current ratio x3.63.4 106.1%  
Inventory Days Days7365 113.1%  
Debtors Days Days10729 365.3%  
Net fixed assets Rs m14,986835 1,793.7%   
Share capital Rs m369213 173.6%   
"Free" reserves Rs m30,35316,715 181.6%   
Net worth Rs m30,76016,928 181.7%   
Long term debt Rs m00-   
Total assets Rs m37,15124,162 153.8%  
Interest coverage x58.6163.7 35.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.61.4 43.1%   
Return on assets %19.116.8 114.1%  
Return on equity %22.623.7 95.4%  
Return on capital %29.336.9 79.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,322369 2,800.7%   
Fx outflow Rs m2,9783,807 78.2%   
Net fx Rs m7,343-3,438 -213.6%   
CASH FLOW
From Operations Rs m4,6361,527 303.6%  
From Investments Rs m-11,155-2,148 519.2%  
From Financial Activity Rs m6,509-1,024 -635.5%  
Net Cashflow Rs m-18-1,646 1.1%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 7.9 99.2%  
FIIs % 16.6 0.1 16,630.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.1 152.0%  
Shareholders   25,395 18,270 139.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SHASUN PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 12, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS